{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:56:18Z","timestamp":1791208578112,"version":"4.1.0"},"reference-count":120,"publisher":"Rockefeller University Press","issue":"6","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD007829"],"award-info":[{"award-number":["R01FD007829"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,2]]},"abstract":"<jats:p>Primary immune regulatory disorders (PIRDs), autoinflammatory, and hyperinflammatory syndromes can be life-threatening and\/or significantly impact quality of life. Targeted immune modulation may control symptoms for some, but allogeneic hematopoietic stem cell transplantation (alloHCT) remains the only cure for many patients. Despite advances in alloHCT, outcomes for this population continue to need optimization. Focus areas include referral timing, patient selection, multidisciplinary evaluation, targeted pretransplant immune suppression (PTIS), graft selection, model- and exposure-based conditioning, and post-alloHCT management. Here, we describe our preferred alloHCT approach for this patient population. This includes early alloHCT referral, continued evaluation to identify an appropriate alloHCT window, 6\u201312 wk of targeted PTIS for inflamed patients, a myeloablative model-based reduced-toxicity conditioning regimen, a strong index of suspicion for posttransplant immune dysregulation, and multidisciplinary long-term follow-up. Emphasis is placed on the need for predictive biomarkers to guide clinical decision-making, objective measurements of long-term response\/disease resolution, and prospective multicenter trials. By refining our approaches, curative outcomes will continue to improve.<\/jats:p>","DOI":"10.70962\/jhi.20250147","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:22:07Z","timestamp":1789021327000},"update-policy":"https:\/\/doi.org\/10.70962\/jhi.crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["How I Treat: Transplantation for primary immune regulatory diseases and inflammatory disorders"],"prefix":"10.70962","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1129-5129","authenticated-orcid":true,"given":"Joseph Hai","family":"Oved","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01esghr10","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University Irving Medical Center 1 Section of Transplantation & Cellular Therapies, Departments of Pediatrics & Medicine, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100509100383100_bib1","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J. Hum. Immun."},{"key":"2026100509100383100_bib2","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","volume":"1","author":"Bousfiha","year":"2025","journal-title":"J. Hum. Immun."},{"key":"2026100509100383100_bib3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/ACI.0000000000000689","article-title":"Primary immune regulatory disorders: A growing universe of immune dysregulation","volume":"20","author":"Chan","year":"2020","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13023-022-02249-1","article-title":"Primary immune regulatory disorders: Undiagnosed needles in the haystack?","volume":"17","author":"Flinn","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"2026100509100383100_bib5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1725282","article-title":"Mapping the landscape of autoimmunity and autoinflammation in inborn errors of immunity: Broad distribution with distinct clustering patterns","volume":"16","author":"Tahiat","year":"2025","journal-title":"Front. Immunol."},{"key":"2026100509100383100_bib6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41584-023-01042-z","article-title":"Treatment of systemic juvenile idiopathic arthritis","volume":"19","author":"Hinze","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"2026100509100383100_bib7","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/ppul.25373","article-title":"Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency","volume":"56","author":"Krone","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"2026100509100383100_bib8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/all.13753","article-title":"Lung disease in STAT3 hyper-IgE syndrome requires intense therapy","volume":"74","author":"Kroner","year":"2019","journal-title":"Allergy"},{"key":"2026100509100383100_bib9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.jaci.2023.08.004","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency","volume":"152","author":"Taghizade","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"2026100509100383100_bib11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","article-title":"JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: An ESID\/EBMT-IEWP retrospective study","volume":"153","author":"Fischer","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib12","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","article-title":"Normalized interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in patients with type I Interferonopathies","volume":"45","author":"Kretzschmar","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"2026100509100383100_bib14","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S2665-9913(20)30342-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: A multicentre, randomised, double-blind, placebo-controlled, phase 2 study","volume":"3","author":"Bruce","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"2026100509100383100_bib15","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/bcp.15133","article-title":"Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach","volume":"88","author":"Jacqmin","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026100509100383100_bib16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026100509100383100_bib17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2024.08.029","article-title":"Systemic T-cell activation and IFN-\u03b3 activity in indeterminate severe hepatitis are reminiscent of hemophagocytic lymphohistiocytosis: Implications for T-cell- and IFN-\u03b3-directed therapies","volume":"155","author":"Nguyen","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib18","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/bloodadvances.2024013690","article-title":"Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH study","volume":"10","author":"Zoref-Lorenz","year":"2025","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-021-08871-4","article-title":"Precision medicine in the treatment of primary immune deficiency patients with disorders of immune dysregulation","volume":"63","author":"Ballow","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2026100509100383100_bib20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2020.00239","article-title":"Hematopoietic cell transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey","volume":"11","author":"Chan","year":"2020","journal-title":"Front. Immunol."},{"key":"2026100509100383100_bib21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Inborn Errors Working Party of the European Society for B, Marrow T, the Primary Immune Deficiency Treatment C. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2026.2641540","article-title":"Novel indications for hematopoietic stem cell transplantation in inborn errors of immunity","volume":"22","author":"Laberko","year":"2026","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2026100509100383100_bib23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbmt.2018.10.003","article-title":"CD3+\/CD19+ Depleted matched and mismatched unrelated donor hematopoietic stem cell transplant with targeted T cell addback is associated with excellent outcomes in pediatric patients with nonmalignant hematologic disorders","volume":"25","author":"Oved","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2026100509100383100_bib24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3324\/haematol.2024.286544","article-title":"Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia","volume":"110","author":"Oved","year":"2025","journal-title":"Haematologica"},{"key":"2026100509100383100_bib25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jtct.2025.10.021","article-title":"Long-term follow-up of the Baltimore experience with hematopoietic cell transplantation for severe aplastic anemia using post-transplantation cyclophosphamide","volume":"32","author":"DeZern","year":"2026","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib26","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood.2023020435","article-title":"Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"key":"2026100509100383100_bib27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(23)00731-6","article-title":"Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: A 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium","volume":"402","author":"Thakar","year":"2023","journal-title":"Lancet"},{"key":"2026100509100383100_bib28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: A study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood"},{"key":"2026100509100383100_bib29","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/bloodadvances.2025017662","article-title":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: A PIDTC report","volume":"10","author":"Alexander","year":"2026","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050026","article-title":"IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts","volume":"5","author":"Rottman","year":"2008","journal-title":"PLoS Med."},{"key":"2026100509100383100_bib31","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3324\/haematol.2019.216101","article-title":"Role of interferon-\u03b3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Merli","year":"2019","journal-title":"Haematologica"},{"key":"2026100509100383100_bib32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28900","article-title":"The role of interferon-gamma and its signaling pathway in pediatric hematological disorders","volume":"68","author":"Merli","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"2026100509100383100_bib33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613644","article-title":"Identification of new soluble factors correlated with the development of graft failure after Haploidentical Hematopoietic Stem Cell Transplantation","volume":"11","author":"Weber","year":"2020","journal-title":"Front. Immunol."},{"key":"2026100509100383100_bib34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1182\/blood.2025030976","article-title":"CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis","volume":"147","author":"Rocco","year":"2025","journal-title":"Blood"},{"key":"2026100509100383100_bib35","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41409-024-02487-w","article-title":"Emapalumab for the treatment of immune-mediated graft failure after HSCT","volume":"60","author":"Merli","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"2026100509100383100_bib36","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692219","article-title":"The use of biologic modifiers as a bridge to hematopoietic cell transplantation in primary immune regulatory disorders","volume":"12","author":"Arnold","year":"2021","journal-title":"Front. Immunol."},{"key":"2026100509100383100_bib38","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2024.08.020","article-title":"Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European society for blood and marrow transplantation inborn errors working party study","volume":"154","author":"Tsilifis","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/MOP.0000000000001401","article-title":"Transplantation for immune dysregulatory disorders: Current themes and future expectations","volume":"36","author":"McClory","year":"2024","journal-title":"Curr. Opin. Pediatr."},{"key":"2026100509100383100_bib40","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.jaip.2026.05.018","article-title":"Hematopoietic stem cell transplant for JAK-STAT disorders","volume":"14","author":"Leiding","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2026100509100383100_bib41","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250027","article-title":"Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging","volume":"1","author":"Buddingh","year":"2025","journal-title":"J. Hum. Immun."},{"key":"2026100509100383100_bib42","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaci.2023.05.016","article-title":"Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations","volume":"152","author":"Kunvarjee","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib43","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood.2024025977","article-title":"Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism","volume":"144","author":"Verkamp","year":"2024","journal-title":"Blood"},{"key":"2026100509100383100_bib44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41409-025-02776-y","article-title":"Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes","volume":"61","author":"Sheikh","year":"2026","journal-title":"Bone Marrow Transpl."},{"key":"2026100509100383100_bib45","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2020.01.002","article-title":"Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen","volume":"26","author":"Anurathapan","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2026100509100383100_bib46","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41409-024-02257-8","article-title":"Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease","volume":"59","author":"F\u00fcrst","year":"2024","journal-title":"Bone Marrow Transpl."},{"key":"2026100509100383100_bib47","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.20248","article-title":"Haematopoietic stem cell transplant for inborn errors of immunity-Who and when?","volume":"207","author":"Oved","year":"2025","journal-title":"Br. J. Haematol."},{"key":"2026100509100383100_bib48","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41586-024-08346-4","article-title":"Monoallelic expression can govern penetrance of inborn errors of immunity","volume":"637","author":"Stewart","year":"2025","journal-title":"Nature"},{"key":"2026100509100383100_bib49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142434","article-title":"Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiency","volume":"131","author":"Pillay","year":"2021","journal-title":"J. Clin. Invest."},{"key":"2026100509100383100_bib50","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood-2018-01-827485","article-title":"Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis","volume":"132","author":"Lucchini","year":"2018","journal-title":"Blood"},{"key":"2026100509100383100_bib51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108993","article-title":"Preemptive hematopoietic cell transplantation for asymptomatic patients with X-linked lymphoproliferative syndrome type 1","volume":"237","author":"Tomomasa","year":"2022","journal-title":"Clin. Immunol."},{"key":"2026100509100383100_bib52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jama.2024.19662","article-title":"Expanded newborn screening using Genome Sequencing for early actionable conditions","volume":"333","author":"Ziegler","year":"2025","journal-title":"JAMA"},{"key":"2026100509100383100_bib53","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo5407","article-title":"FOXP3 exon 2 controls Treg stability and autoimmunity","volume":"7","author":"Du","year":"2022","journal-title":"Sci. Immunol."},{"key":"2026100509100383100_bib54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood.2022015482","article-title":"Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity","volume":"141","author":"Cheminant","year":"2023","journal-title":"Blood"},{"key":"2026100509100383100_bib55","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.2020008187","article-title":"How I use allogeneic HSCT for adults with inborn errors of immunity","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"key":"2026100509100383100_bib56","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood.2022015506","article-title":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: An EBMT IEWP study","volume":"140","author":"Albert","year":"2022","journal-title":"Blood"},{"key":"2026100509100383100_bib57","doi-asserted-by":"publisher","first-page":"259.e1","DOI":"10.1016\/j.jtct.2025.02.002","article-title":"Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning","volume":"31","author":"Dvorak","year":"2025","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib58","doi-asserted-by":"publisher","first-page":"101 e1","DOI":"10.1016\/j.jtct.2023.09.024","article-title":"Age impacts risk of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for non-severe combined immune deficiency inborn errors of immunity","volume":"30","author":"Fitch","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib59","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"key":"2026100509100383100_bib60","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2026100509100383100_bib61","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood-2018-09-876284","article-title":"The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases","volume":"133","author":"Thakar","year":"2019","journal-title":"Blood"},{"key":"2026100509100383100_bib62","doi-asserted-by":"publisher","first-page":"125.e1","DOI":"10.1016\/j.jtct.2022.11.020","article-title":"Expanded HCT-CI definitions capture Comorbidity better for younger patients of allogeneic HCT for nonmalignant diseases","volume":"29","author":"Broglie","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib63","doi-asserted-by":"publisher","first-page":"74.e1","DOI":"10.1016\/j.bbmt.2020.10.003","article-title":"Limitations of applying the hematopoietic cell transplantation comorbidity index in pediatric patients receiving allogeneic hematopoietic cell transplantation","volume":"27","author":"Broglie","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib64","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.jaip.2026.05.015","article-title":"Primary Immune Regulatory Disorders (PIRD): Tools for diagnosis and disease activity assessment to guide therapy","volume":"14","author":"Oved","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2026100509100383100_bib65","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s10875-021-01177-2","article-title":"The immune deficiency and dysregulation activity (IDDA2.1 \u2018Kaleidoscope\u2019) score and other clinical measures in inborn errors of immunity","volume":"42","author":"Seidel","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"2026100509100383100_bib66","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jaci.2025.10.022","article-title":"Machine learning-assisted diagnosis classification of primary immune dysregulation using IDDA2.1 phenotype profiling","volume":"157","author":"Schwitzkowski","year":"2026","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10875-024-01854-y","article-title":"Pre-transplant immune dysregulation predicts for poor outcome following allogeneic haematopoietic stem cell transplantation in adolescents and adults with inborn errors of immunity (IEI)","volume":"45","author":"Fox","year":"2025","journal-title":"J. Clin. Immunol."},{"key":"2026100509100383100_bib68","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.jaip.2026.05.025","article-title":"IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for patients with inborn errors of immunity from the Primary Immune Deficiency Treatment Consortium (PIDTC)","volume":"14","author":"Arnold","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2026100509100383100_bib69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311706","article-title":"JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events","volume":"20","author":"Gurevic","year":"2025","journal-title":"PLoS One"},{"key":"2026100509100383100_bib70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: Incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J."},{"key":"2026100509100383100_bib71","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1182\/bloodadvances.2021005231","article-title":"Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure","volume":"5","author":"Sabulski","year":"2021","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib72","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40744-024-00669-y","article-title":"Population pharmacokinetics of the anti-interferon-gamma monoclonal antibody emapalumab: An updated analysis","volume":"11","author":"Brossard","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"2026100509100383100_bib73","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2026100509100383100_bib74","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/hon.2769","article-title":"Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib","volume":"38","author":"Rumi","year":"2020","journal-title":"Hematol. Oncol."},{"key":"2026100509100383100_bib75","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.107005","article-title":"Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease","volume":"125","author":"Lebon","year":"2023","journal-title":"Leuk. Res."},{"key":"2026100509100383100_bib76","doi-asserted-by":"publisher","first-page":"518.e1","DOI":"10.1016\/j.jtct.2024.02.025","article-title":"Long-term clinical outcomes and B cell immune reconstitution following Allo-HCT with prophylactic, post-transplant rituximab","volume":"30","author":"Kennedy","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib77","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jcyt.2024.01.005","article-title":"Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Major-Monfried","year":"2024","journal-title":"Cytotherapy"},{"key":"2026100509100383100_bib78","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.bbmt.2017.06.013","article-title":"Durable chimerism and long-term survival after unrelated umbilical cord blood transplantation for pediatric hemophagocytic lymphohistiocytosis: A single-center experience","volume":"23","author":"Patel","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2026100509100383100_bib79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41409-025-02735-7","article-title":"Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT","volume":"61","author":"Rocha","year":"2026","journal-title":"Bone Marrow Transpl."},{"key":"2026100509100383100_bib80","doi-asserted-by":"publisher","first-page":"296.e1","DOI":"10.1016\/j.jtct.2025.10.012","article-title":"Peripheral blood or bone marrow grafts for mismatched unrelated donors with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"32","author":"Arcuri","year":"2026","journal-title":"Transpl. Cell Ther."},{"key":"2026100509100383100_bib81","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): A multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol."},{"key":"2026100509100383100_bib82","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41409-026-02906-0","article-title":"Updated EBMT\/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism","volume":"61","author":"Albert","year":"2026","journal-title":"Bone Marrow Transpl."},{"key":"2026100509100383100_bib83","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.805189","article-title":"Serotherapy as graft-versus-host disease prophylaxis in haematopoietic stem cell transplantation for Acute lymphoblastic leukaemia","volume":"9","author":"Keogh","year":"2021","journal-title":"Front. Pediatr."},{"key":"2026100509100383100_bib84","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1182\/bloodadvances.2024014836","article-title":"Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation","volume":"9","author":"Admiraal","year":"2025","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib85","doi-asserted-by":"publisher","first-page":"810 e1","DOI":"10.1016\/j.jtct.2024.05.015","article-title":"Model-based antithymocyte globulin in \u03b1\u03b2haplo-hematopoietic stem cell transplantation facilitates engraftment, expedites T cell recovery, and mitigates the risk of acute graft-versus-host disease","volume":"30","author":"Barbarito","year":"2024","journal-title":"Transpl. Cell Ther"},{"key":"2026100509100383100_bib86","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jcyt.2024.01.004","article-title":"Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients","volume":"26","author":"Lakkaraja","year":"2024","journal-title":"Cytotherapy"},{"key":"2026100509100383100_bib87","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): A single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol."},{"key":"2026100509100383100_bib88","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: A multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"key":"2026100509100383100_bib89","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bcp.14955","article-title":"Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation","volume":"88","author":"Dong","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026100509100383100_bib90","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1182\/bloodadvances.2022009051","article-title":"Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: The ARTIC study","volume":"7","author":"Achini-Gutzwiller","year":"2023","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib91","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1038\/s41409-021-01460-1","article-title":"A prospective pilot study of a novel alemtuzumab target concentration intervention strategy","volume":"56","author":"Arnold","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"2026100509100383100_bib92","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","article-title":"Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity","volume":"8","author":"Bogn\u00e0r","year":"2024","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib93","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: A multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"2026100509100383100_bib94","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib95","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood.2021014687","article-title":"Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: An EBMT inborn errors working party analysis","volume":"139","author":"Albert","year":"2022","journal-title":"Blood"},{"key":"2026100509100383100_bib96","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood"},{"key":"2026100509100383100_bib97","doi-asserted-by":"publisher","first-page":"470.e1","DOI":"10.1016\/j.jtct.2025.11.028","article-title":"Alemtuzumab, Fludarabine, Melphalan, and Thiotepa conditioning for transplantation in inborn errors of immunity","volume":"32","author":"Pfeiffer","year":"2025","journal-title":"Transpl. Cell Ther"},{"key":"2026100509100383100_bib98","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.bbmt.2018.03.013","article-title":"Post-transplant CD34+ selected stem cell \u201cBoost\u201d for mixed chimerism after reduced-intensity conditioning hematopoietic stem cell transplantation in children and young adults with primary immune deficiencies","volume":"24","author":"Chandra","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2026100509100383100_bib99","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood.2024024038","article-title":"Outcomes of HLA-mismatched HSCT with TCR\u03b1\u03b2\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity","volume":"144","author":"Lum","year":"2024","journal-title":"Blood"},{"key":"2026100509100383100_bib100","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102662","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: Current status and optimization strategies","volume":"97","author":"Fuji","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"2026100509100383100_bib101","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10875-025-01978-9","article-title":"\u03b1\u03b2T\/CD19-depleted allogeneic stem cell transplantation in adults with inborn errors of immunity","volume":"46","author":"de Winter","year":"2026","journal-title":"J. Clin. Immunol."},{"key":"2026100509100383100_bib102","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/bloodadvances.2020004072","article-title":"T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity","volume":"6","author":"Lum","year":"2022","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib103","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7028","article-title":"Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease","volume":"12","author":"Strobl","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"2026100509100383100_bib104","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1016\/S2665-9913(24)00275-3","article-title":"Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: Outcomes from an international, retrospective cohort study","volume":"7","author":"Matt","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"2026100509100383100_bib105","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.cgh.2025.03.018","article-title":"Outcomes of allogeneic hematopoietic stem cell transplant in Monogenic inflammatory Bowel disease","volume":"23","author":"Baccarella","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2026100509100383100_bib106","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1182\/bloodadvances.2025016915","article-title":"Harmonized immune recovery monitoring after HCT: Evidence and practical guidance from the Westhafen Intercontinental Group","volume":"9","author":"Hammoudi","year":"2025","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib107","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaci.2020.04.033","article-title":"Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency","volume":"147","author":"Castiello","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib108","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jaci.2023.07.017","article-title":"Transplantation after CD45-ADC corrects Rag1 immunodeficiency in congenic and haploidentical settings","volume":"153","author":"Pala","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib109","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-07456-3","article-title":"Selective haematological cancer eradication with preserved haematopoiesis","volume":"630","author":"Garaud\u00e9","year":"2024","journal-title":"Nature"},{"key":"2026100509100383100_bib110","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1182\/bloodadvances.2023012457","article-title":"Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation","volume":"8","author":"Persaud","year":"2024","journal-title":"Blood Adv."},{"key":"2026100509100383100_bib111","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood.2025031858","article-title":"Nonmyeloablative conditioning combined with the anti-CD117 antibody Briquilimab in Older adults with high-risk AML and MDS","volume":"147","author":"Muffly","year":"2026","journal-title":"Blood"},{"key":"2026100509100383100_bib112","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: A phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat. Med."},{"key":"2026100509100383100_bib113","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized phase III SIERRA trial of 131I-Apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026100509100383100_bib114","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"2026100509100383100_bib115","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1182\/blood.2023023549","article-title":"Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice","volume":"143","author":"Saha","year":"2024","journal-title":"Blood"},{"key":"2026100509100383100_bib116","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: Interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol."},{"key":"2026100509100383100_bib117","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2017.01282","article-title":"Forkhead-Box-P3 gene Transfer in human CD4+ T Conventional cells for the generation of stable and efficient regulatory T cells, suitable for immune modulatory therapy","volume":"8","author":"Passerini","year":"2017","journal-title":"Front. Immunol."},{"key":"2026100509100383100_bib118","doi-asserted-by":"publisher","first-page":"828489","DOI":"10.3389\/fgeed.2022.828489","article-title":"Genome editing with TALEN, CRISPR-Cas9 and CRISPR-Cas12a in combination with AAV6 homology donor restores T cell function for XLP","volume":"4","author":"Houghton","year":"2022","journal-title":"Front. Genome"},{"key":"2026100509100383100_bib119","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaci.2023.08.003","article-title":"Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis","volume":"153","author":"Dettmer-Monaco","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026100509100383100_bib120","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2019.329","article-title":"Lentiviral gene therapy for familial hemophagocytic lymphohistiocytosis type 3, caused by UNC13D genetic defects","volume":"31","author":"Takushi","year":"2020","journal-title":"Hum. Gene Ther."}],"container-title":["Journal of Human Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jhi\/article-pdf\/doi\/10.70962\/jhi.20250147\/2041377\/jhi_20250147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jhi\/article-pdf\/doi\/10.70962\/jhi.20250147\/2041377\/jhi_20250147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:10:14Z","timestamp":1791205814000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jhi\/article\/2\/6\/e20250147\/283043\/How-I-Treat-Transplantation-for-primary-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11,2]]}},"URL":"https:\/\/doi.org\/10.70962\/jhi.20250147","relation":{},"ISSN":["3065-8993"],"issn-type":[{"value":"3065-8993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"e20250147"}}